Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK51155 Tablets

Haisco Pharmaceutical Group Co., Ltd.·August 18, 2026·2 pages

✨ AI Summary

Haichang Pharmaceutical Group announced it received approval from the NMPA for clinical trials of its innovative drug HSK51155 tablets. This oral small molecule analgesic drug is intended for pain-related treatments. The company has also entered into a collaboration with AbbVie for global development and commercialization, potentially worth over $700 million.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 002653

Securities Abbreviation: Haichang Pharma

Announcement No.: 2026-091

Haichang Pharmaceutical Group Co., Ltd.

Announcement on Obtaining the "Drug Clinical Trial Approval Notice" for Innovative Drug HSK51155 Tablets

The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and are free from any false records, misleading statements, or material omissions.

Haichang Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company") recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The basic situation is as follows:

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.